Peptide Research Profile

Retatrutide

LY3437943 — Triple GIP/GLP-1/Glucagon Receptor Agonist (Eli Lilly)

Evidence Grade: Phase 2 RCT (NEJM 2023) · Investigational Drug

A first-in-class triple-agonist peptide simultaneously targeting GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, retatrutide achieved unprecedented weight loss of 24.2% at 48 weeks in a Phase 2 randomized controlled trial published in the New England Journal of Medicine (2023). Currently in Phase 3 trials for obesity. This is an investigational pharmaceutical — NOT available through compounding pharmacies or gray-market peptide suppliers. Included here for educational completeness.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Retatrutide is an investigational drug in active clinical development. It is NOT approved by any regulatory agency and is NOT available through compounding or gray-market channels. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

Triple Agonist

GIP + GLP-1 + Glucagon receptor agonist — first-in-class triple incretin

Developer

Eli Lilly

LY3437943 — Phase 3 trials ongoing (2024–2026)

Evidence Level

Phase 2 RCT

NEJM 2023 • n=338 • 48-week data • 24.2% weight loss at highest dose

Key Pathway

GIP/GLP-1/GCGR

Tri-agonism: incretin + glucagon signaling for appetite, glucose, and energy expenditure

Pharmacology

Mechanism of action

Retatrutide represents the next evolution beyond dual-agonists (tirzepatide) by adding glucagon receptor activation to the GIP + GLP-1 backbone. This triple agonism addresses obesity through three complementary mechanisms: appetite suppression (GLP-1), enhanced insulin-mediated nutrient disposal (GIP), and increased energy expenditure / hepatic fat mobilization (glucagon). The addition of glucagon agonism is the key differentiator — it turns a metabolic brake into an active energy-burning signal.

Subcutaneous Injection & Sustained Release

Administered as a once-weekly subcutaneous injection. The peptide’s molecular modifications (fatty acid acylation and amino acid substitutions) create prolonged albumin binding and resistance to DPP-4 cleavage, producing a functional half-life of ~6 days. This allows stable receptor activation throughout the dosing interval without the peaks and troughs of native GLP-1 (half-life: 2 minutes).

Engineering details: Like semaglutide and tirzepatide, retatrutide uses a C18 fatty acid linker that non-covalently binds serum albumin, creating a circulating depot. DPP-4 resistance is achieved through an Aib (aminoisobutyric acid) substitution at position 2. The tri-agonist activity comes from a chimeric peptide backbone that preserves binding epitopes for all three receptors — an engineering challenge because GIP-R, GLP-1R, and GCGR have overlapping but distinct binding pockets in the same receptor family (Class B GPCRs).

GLP-1 Receptor Activation — Appetite & Glucose

The GLP-1 receptor agonist component activates receptors in the hypothalamic arcuate nucleus, area postrema, and nucleus tractus solitarius, producing potent appetite suppression and early satiety. Simultaneously, GLP-1R activation in pancreatic beta cells enhances glucose-dependent insulin secretion (no hypoglycemia risk in euglycemic states). Gastric emptying is delayed, prolonging post-meal satiety.

Central GLP-1R signaling: GLP-1 receptors in the hypothalamus activate POMC/CART neurons (anorexigenic) and inhibit NPY/AgRP neurons (orexigenic). In the hindbrain, area postrema and NTS activation integrates visceral satiety signals. The nausea associated with GLP-1 agonists is partially mediated by area postrema activation — this is a dose-dependent on-target effect, not an off-target side effect. Peripheral GLP-1R on vagal afferents provides an additional gut-brain satiety signal.

GIP Receptor Activation — Nutrient Handling & Fat Metabolism

GIP (glucose-dependent insulinotropic polypeptide) receptor activation enhances beta cell insulin secretion synergistically with GLP-1, producing superior glycemic control compared to GLP-1 alone. GIP-R activation in adipose tissue may improve lipid buffering capacity and insulin sensitivity in fat cells. The combination of GIP + GLP-1 agonism is what makes tirzepatide outperform semaglutide; retatrutide builds on this foundation.

GIP paradox: GIP receptor’s role in obesity is debated. GIP-R knockout mice are resistant to diet-induced obesity, yet GIP agonism in tirzepatide and retatrutide produces more weight loss than GLP-1 alone. The resolution may involve pharmacological GIP-R agonism at supraphysiological levels desensitizing the receptor (functional antagonism), or GIP’s central effects on hypothalamic energy regulation differing from peripheral effects on adipocytes. This remains an active area of research and is not fully resolved.

Glucagon Receptor Activation — Energy Expenditure

The novel glucagon receptor (GCGR) agonist component is what distinguishes retatrutide from tirzepatide. Glucagon activates hepatic glycogenolysis, gluconeogenesis, and critically, increases energy expenditure through brown adipose tissue thermogenesis and hepatic fatty acid oxidation. This means the body burns more calories at rest. Glucagon also promotes hepatic fat mobilization, which may explain the dramatic liver fat reductions seen in trials (up to 86% reduction in hepatic steatosis).

Glucagon thermogenesis: GCGR activation in brown adipose tissue (BAT) upregulates UCP1 (uncoupling protein 1), which dissipates the mitochondrial proton gradient as heat rather than ATP. This is the same pathway activated by cold exposure. In the liver, glucagon stimulates fatty acid beta-oxidation via AMPK activation and inhibition of acetyl-CoA carboxylase (ACC), reducing de novo lipogenesis while increasing fat burning. The risk of glucagon agonism is hyperglycemia, but the concurrent GLP-1 and GIP agonism counterbalance this — the glucose-raising effect of glucagon is offset by the insulin-enhancing effects of the incretin components.

Integrated Tri-Agonist Effect

The three receptor activities are not merely additive — they are synergistic and self-balancing. GLP-1 suppresses appetite and enhances insulin. GIP enhances insulin further and improves fat cell function. Glucagon increases energy expenditure and fat burning but would raise glucose if given alone — the GLP-1/GIP components prevent this. The net result is aggressive weight loss with maintained glycemic control, which is why retatrutide’s 24.2% weight loss exceeds both semaglutide (~15%) and tirzepatide (~22%) at comparable timepoints.

Dose-titration schedule: The Phase 2 trial used a careful up-titration (starting at 0.5 mg, escalating monthly to the target dose of 12 mg) specifically because glucagon agonism adds metabolic stress that must be counterbalanced by the incretin components establishing their effects first. The GI side effects (nausea, vomiting, diarrhea) are front-loaded during titration and diminish with continued dosing, similar to other incretin therapies but potentially more intense due to the additional glucagon axis.

Administration

Delivery routes

Subcutaneous Injection

Only Route — Clinical Trial Protocol

Once-weekly subcutaneous injection in the abdomen, thigh, or upper arm. Auto-injector pen format in clinical trials (similar to Ozempic or Mounjaro pens). The fatty acid acylation enables the weekly dosing schedule through sustained albumin-bound circulation. This is the only route being developed.

Oral

Not Developed

No oral formulation is in development for retatrutide. While oral semaglutide exists (Rybelsus), the added complexity of triple-agonist pharmacology and the need for precise receptor activation ratios makes an oral formulation significantly more challenging. Not expected in the near future.

Other Routes

Not Applicable

Intranasal, sublingual, and transdermal routes are not being developed. The molecule’s size (~4.5 kDa) and the precision dosing requirements of tri-agonism make subcutaneous injection the only practical delivery method. Unlike older peptides, retatrutide is not available as a lyophilized powder for reconstitution.

Gray Market / Compounding

NOT Available — Warning

Retatrutide is NOT available through compounding pharmacies, research chemical suppliers, or gray-market peptide vendors. Any product claiming to be retatrutide from non-pharmaceutical sources should be considered unverified and potentially dangerous. The molecule is patent-protected by Eli Lilly and has no compounding exemption. If you encounter “retatrutide” for sale online, it is either counterfeit, mislabeled, or an entirely different compound.

Protocols

Dosing reference

Dosing data comes exclusively from the Phase 2 NEJM trial. Retatrutide is an investigational drug and no established clinical dosing guidelines exist outside of active clinical trial protocols.

Context	Dose	Frequency	Source
Phase 2 highest efficacy dose	12 mg/week After 4-month titration from 0.5 mg	Once weekly SC injection	Jastreboff et al., NEJM 2023
Phase 2 moderate dose	8 mg/week After titration from 0.5 mg	Once weekly SC injection	Jastreboff et al., NEJM 2023
Phase 2 low dose	4 mg/week Multiple titration schedules tested	Once weekly SC injection	Jastreboff et al., NEJM 2023
Starting dose (all arms)	0.5 mg/week Mandatory starting dose	Once weekly SC injection	Jastreboff et al., NEJM 2023

Important: These doses were administered under clinical trial supervision with regular monitoring. Retatrutide is not available for self-administration. Attempting to obtain or use this compound outside of a clinical trial is not recommended. Phase 3 trials may establish different optimal doses.

Outcomes

Benefits & side effects

Reported Benefits

Unprecedented Weight Loss

24.2% mean body weight reduction at 48 weeks at the 12 mg dose — the highest weight loss ever reported for a pharmacological agent in a Phase 2 trial. This exceeds semaglutide 2.4 mg (~15%) and tirzepatide 15 mg (~22%) at comparable timepoints. 100% of participants in the 12 mg group lost ≥5% body weight. Nearly 25% achieved ≥30% weight loss.

Phase 2 RCT • NEJM 2023 • n=338 • 48 weeks

Dramatic Liver Fat Reduction

In a sub-study, retatrutide reduced hepatic fat content by up to 86% at 48 weeks. This suggests potential efficacy in MASLD/MASH (formerly NAFLD/NASH), where no approved pharmacotherapy currently exists. The glucagon component’s hepatic fat mobilization effect is the likely driver.

Phase 2 sub-study • Liver MRI-PDFF • Small sample

Glycemic Control

In the Phase 2 diabetes cohort, retatrutide produced HbA1c reductions of up to 2.2 percentage points, bringing most participants to target (<7%) or even to normoglycemia (<5.7%). This is competitive with or exceeds the best available diabetes medications.

Phase 2 • Type 2 diabetes subgroup • n=45 in highest dose arm

Potential Cardiovascular Benefit

Significant improvements in blood pressure, triglycerides, and waist circumference were observed across dose groups. Cardiovascular outcomes trials (CVOTs) are planned but not yet completed. Given the class effect seen with semaglutide (STEP-HFpEF, SELECT), cardiovascular benefit is plausible but unproven.

Phase 2 secondary endpoints • CVOT pending

Adverse Effects & Risks

Gastrointestinal Events

Nausea (45% at 12 mg), diarrhea (34%), vomiting (18%), and constipation (16%) were the most common adverse events. Most were mild-to-moderate and occurred during dose titration. GI events are a class effect of incretin agonists, potentially amplified by the glucagon component. Slower titration schedules reduced GI severity.

Phase 2 AE data • Dose-dependent • Front-loaded during titration

Increased Heart Rate

Mean heart rate increased by 4–6 bpm at the highest dose. This is consistent with other GLP-1 agonists and likely reflects autonomic effects of central GLP-1R activation. Clinical significance is unknown pending CVOT data, but it is a monitored safety signal in Phase 3.

Phase 2 safety data • Consistent with GLP-1 class effect

Cholelithiasis Risk

Rapid weight loss from any cause increases gallstone risk due to changes in bile composition. GLP-1 agonists may additionally reduce gallbladder motility. Clinical trial monitoring includes gallbladder assessment. Approximately 2–3% of participants experienced gallbladder-related events.

Phase 2 • Class effect of rapid weight loss + GLP-1 agonism

Unknown Long-Term Risks

As a novel triple-agonist, the long-term consequences of chronic glucagon receptor agonism alongside incretin activation are unknown. Theoretical concerns include: pancreatic effects (pancreatitis, neoplasia — class-wide GLP-1 concern), bone density effects with prolonged weight loss, thyroid C-cell effects (rodent-specific signal for GLP-1 agonists), and effects of maintained supraphysiological glucagon tone on hepatic metabolism.

Theoretical — Phase 3 and post-marketing surveillance needed

Muscle Mass Loss

Like all aggressive weight-loss interventions, retatrutide-induced weight loss includes some lean mass reduction. The Phase 2 trial did not include body composition endpoints (DEXA), so the lean-to-fat mass loss ratio is unknown. This is a key Phase 3 question, as sarcopenia during rapid weight loss is a recognized clinical concern.

Inferred from weight loss magnitude • Body composition data not collected in Phase 2

Evidence Base

Key studies

Phase 2 Randomized Controlled Trial

Triple-Hormone-Receptor Agonist Retatrutide for Obesity

Jastreboff et al. • New England Journal of Medicine • 2023 • n=338

Design & Findings

48-week, double-blind, placebo-controlled trial across 9 dose groups in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. The 12 mg group achieved mean weight loss of 24.2% from baseline. All active-dose groups significantly outperformed placebo. Weight loss trajectory had not plateaued at 48 weeks, suggesting further loss possible with longer treatment.

Significance

Published in the highest-impact medical journal. Establishes retatrutide as the most effective pharmacological weight-loss agent in clinical development. The non-plateauing weight curve at 48 weeks is particularly notable — most GLP-1 agonists plateau at 60–68 weeks.

Limitations

Phase 2 sample size (n=338 across 9 groups, so ~40 per dose arm). 48-week duration — long-term efficacy maintenance and safety beyond 1 year unknown. Predominantly White/Caucasian study population. No body composition (DEXA) data. No cardiovascular or hepatic histology outcomes.

View on PubMed

Phase 2 Sub-Study — MASLD/Liver Fat

Effects of Retatrutide on Liver Fat in Patients with Obesity

Sanyal et al. • New England Journal of Medicine • 2024 • n=98 (MASLD subgroup)

Design & Findings

Among participants with baseline hepatic steatosis (≥10% liver fat by MRI-PDFF), retatrutide 12 mg reduced liver fat content from a baseline mean of ~16% to ~2% at 48 weeks. 86% relative reduction. Most participants achieved complete resolution of steatosis (<5% liver fat).

Significance

MASLD/MASH has no approved pharmacotherapy. These reductions exceed those seen with semaglutide or pioglitazone. The glucagon component’s hepatic fat oxidation mechanism provides a compelling rationale for this dramatic effect.

Limitations

Small sub-study sample (n=98). MRI-PDFF measures fat content, not fibrosis resolution or inflammation (NASH histology). No liver biopsy data. Dedicated Phase 3 MASH trial needed with histological endpoints.

View on PubMed

Phase 2 — Type 2 Diabetes

Retatrutide in Adults with Type 2 Diabetes

Rosenstock et al. • The Lancet • 2023 • n=281

Design & Findings

In adults with T2D, retatrutide 12 mg produced HbA1c reductions of up to 2.2 percentage points vs. 0.01% for placebo at 36 weeks. 71% of participants in the highest dose group achieved HbA1c <5.7% (normoglycemia). Concurrent weight loss of up to 16.9% at 36 weeks in the diabetes population.

Significance

Demonstrates that tri-agonism is effective in the metabolically complex T2D population, not just in non-diabetic obesity. The normoglycemia rate (71%) is remarkable — most diabetes drugs aim for <7%, not reversal to normal levels.

Limitations

Phase 2 sample size. 36-week diabetes-specific data (shorter than the 48-week obesity study). No CVOT data. Hypoglycemia risk with concurrent sulfonylureas or insulin not adequately studied. No comparison to tirzepatide.

View on PubMed

Open Questions

Research gaps

Phase 3 Data Pending

Eli Lilly’s Phase 3 program (TRIUMPH trials) is actively enrolling. Until Phase 3 results, efficacy and safety profiles cannot be considered established. Phase 2 sample sizes (~40 per dose arm) are insufficient to detect rare events like pancreatitis, thyroid carcinoma, or suicidality.

Long-Term Durability Unknown

What happens when retatrutide is discontinued? The weight regain observed with semaglutide (STEP 1 extension) and tirzepatide (SURMOUNT-4) suggests GLP-1-class agents require indefinite treatment. Does the glucagon component alter this trajectory? Unknown. No discontinuation data exists for retatrutide.

Body Composition Data Missing

The Phase 2 trial measured weight but not composition. At 24.2% weight loss, the lean mass loss percentage is clinically critical. If lean mass loss exceeds 30–40% of total weight lost (as typical for caloric restriction), this could produce clinically significant sarcopenia, especially in older adults. DEXA sub-studies are needed in Phase 3.

Cardiovascular Outcomes Unproven

While semaglutide has shown CV benefit in SELECT, retatrutide’s added glucagon agonism creates uncertainty. Glucagon increases heart rate and hepatic glucose output. The net cardiovascular effect of long-term tri-agonism is unknown and requires a dedicated CVOT with hard endpoints (MACE).

MASLD Histology Not Assessed

Liver fat reduction by MRI-PDFF is a surrogate marker. Resolution of NASH (steatohepatitis with inflammation and fibrosis) requires liver biopsy confirmation. Retatrutide’s impact on hepatic inflammation (lobular inflammation, ballooning) and fibrosis stage is unknown.

Accessibility & Equity

If approved, retatrutide will likely cost $1,000–1,500/month (comparable to Mounjaro/Zepbound). Insurance coverage for obesity medications remains inconsistent in the US. Medicare Part D does not cover anti-obesity medications. The population most affected by obesity has the least access to expensive branded pharmaceuticals.

Citations

References & further reading

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PubMed

2. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544. PubMed

3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2024;390(2):168-178. PubMed

4. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(8):1234-1247. PubMed

5. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. PubMed

All Retatrutide on PubMed → ← Back to Research Library